Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
UTMD · NASDAQ · Surgical & Medical Instruments & Apparatus
Utah Medical Products (UTMD) · oqro.io/stocks/UTMD · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$71.97−1.66 (−2.25%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
+28.3% (+$15.86) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $56.11 on Nov 13, 2025 to $71.97 on Nov 13, 2026 (+28.3%). Disclosed in this range: 1 insider trade, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in Midvale, Ut.
Last 12 months
+28.3%
Market value
$229M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 151K shares sold short (4.8% of shares outstanding), +7.9% vs the previous count, 3.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$8.53M
−14.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$11.4M
This quarter $1.25M, a year earlier $2.82M
Net cash
$87.3M
Debt $195K, cash $87.5M, at Jun 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 22, 2026.
Revenue, fiscal 2025
$38.5M
−5.8% vs the year before
Net income
Not reported
As reported in the annual filing
Shares outstanding
3.18M
As of Aug 11, 2026
In fiscal 2025 the company spent $8.36M buying back its own shares and $3.98M on dividends. Cash actually paid, from its cash-flow statement.
Insider buying
First insider buy since Aug 2011Traded Oct 29 · filed the same day
Since the trade +7.7% · S&P 500 −1.9% · to Nov 13
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Yes. Insiders of Utah Medical Products (UTMD) filed 1 open-market purchase in the last 90 days; the latest was filed on Oct 29, 2026.
Since 2006, Utah Medical Products insiders reported 7 open-market purchases and 153 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2026.
No open-market sale by an insider of Utah Medical Products (UTMD) was filed with the SEC in the last 90 days.
No trade in Utah Medical Products (UTMD) was disclosed by a member of Congress in the last 12 months.
Utah Medical Products's next results are expected on Jan 27, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Insiders of Utah Medical Products reported 7 open-market purchases and 153 sales since 2006; purchases in 4 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $67K1×1 trade | — |
| 2023 | — | $65K1×1 trade |
| 2022 | — | $229K4×4 trades |
| 2021 | — | $1.12M8×8 trades |
| 2020 | — | $1.33M10×10 trades |
| 2019 | — | $1.01M13×13 trades |
| 2018 | — | $5.22M27×27 trades |
| 2016 | — | $1.66M23×23 trades |
| 2014 | — | $649K10×10 trades |
| 2013 | — | $2.12M24×24 trades |
| 2012 | — | $351K13×13 trades |
| 2011 | $58K2×2 trades | — |
| 2010 | $74K2×2 trades | — |
| 2009 | $8.8K2×2 trades | $1.03M17×17 trades |
| 2008 | — | $18K1×1 trade |
| 2007 | — | $30K1×1 trade |
| 2006 | — | $30K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 11, 2025, UTMD is up 25.8% and the index fund is up 10.4%: 15 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much UTMD moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Last results
Oct 22, 2026
Within the 30 days after it, until Nov 21, 2026
Next results, expected
Jan 27, 2027
Purchases after results
Not enough history
From Utah Medical Products's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Utah Medical Products's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
